IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1126-1150 out of 1244.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 6-Nov-2013
Scandinavian Journal of Gastroenterology
Genetic aberration paves the way for new treatment of cancer disease
Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients. The discovery gives hope for a new and efficient treatment of colorectal cancer, which is a frequent and often fatal disease. The research was recently published in Scandinavian Journal of Gastroenterology.

Contact: Nils Brünner
nbr@sund.ku.dk
45-26-14-47-08
University of Copenhagen

Public Release: 6-Nov-2013
Hepatology
Discovered a mechanism that induces migration of tumor cells in liver cancer
Researchers from the Biological clues of the invasive and metastatic phenotype group of the Bellvitge Biomedical Research Institute led by Isabel Fabregat have discovered the relationship between the TGFb signalling pathways and CXCR4 in hepatocellular carcinoma . The cytokine TGFb is dependent of CXCR4 to induce tumor cell migratory ability.

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-129
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 6-Nov-2013
Applied Physiology, Nutrition and Metabolism
Health benefits of wild blueberries abound: Study
New research published today in the journal Applied Physiology, Nutrition, and Metabolism, shows that regular long-term wild blueberry diets may help improve or prevent pathologies associated with the metabolic syndrome, including cardiovascular disease and diabetes.

Contact: Jenny Ryan
jenny.ryan@nrcresearchpress.com
Canadian Science Publishing (NRC Research Press)

Public Release: 6-Nov-2013
Angewandte Chemie
OU natural products discovery group asks for public's help with citizen science program
The University of Oklahoma Natural Products Discovery Group has taken an unconventional approach to finding new compounds with therapeutic relevance by launching a crowdsourcing initiative with citizen scientists from around the country. OU researchers team with the public to sample soils from all across the United States for the purpose of identifying new microorganisms that produce drug-like compounds.
National Institutes of Health

Contact: Jana Smith
jana.smith@ou.edu
405-325-1322
University of Oklahoma

Public Release: 6-Nov-2013
Lancet Oncology
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer
Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1 percent difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. The authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients.
Sanofi -Aventis, NIH/National Cancer Institute, Norwegian and Swedish Cancer Societies, Cancer Research UK, Ligue Nationale Contre le Cancer

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 6-Nov-2013
Cancer
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study
Results of an EORTC study published in Cancer point out the prognostic value of baseline recorded health-related quality of life for survival for eleven types of cancer: brain, breast, colorectal, esophageal, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and testicular cancer. For each cancer site, at least one health-related quality of life parameter provided additional prognostic information over and above the clinical and sociodemographic variables.
Pfizer Foundation, European Organisation for Research and Treatment of Cancer Charitable Trust, NIH/National Cancer Institute

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 6-Nov-2013
2013 American Society for Clinical Pathology Annual Meeting
MU study finds more accurate method to diagnose pancreatic cancer
Researchers from the University of Missouri School of Medicine have found a more accurate laboratory method of diagnosing pancreatic cancer, the fourth leading cause of cancer death in the United States. The method uses identification of four traits found in microscopic biopsies of pancreatic tissue.

Contact: Colin Planalp
planalpc@health.missouri.edu
573-884-1935
University of Missouri-Columbia

Public Release: 6-Nov-2013
5th International Scientific Symposium on Tea and Human Health
American Journal of Clinical Nutrition
New research shows tea may help promote weight loss, improve heart health and slow progression of prostate cancer
The December 2013 issue of the American Journal of Clinical Nutrition features 12 new articles about the relationship between tea and human health. Each paper is based on presentations from world-renowned scientists who participated in the Fifth International Scientific Symposium on Tea and Human Health, held at USDA in September 2012.

Contact: Valerie Kulbersh
vkulbersh@pollock-pr.com
212-941-1414
Pollock Communications

Public Release: 6-Nov-2013
PLOS ONE
Researchers help make pediatric eye cancer easier to detect
Can parents use digital cameras and smart phones to potentially screen their children for the most common form of pediatric eye cancer? Baylor University and Harvard Medical School researchers believe so. Findings in PLOS One.

Contact: Mary Leach
Mary_Leach@meei.harvard.edu
Massachusetts Eye and Ear Infirmary

Public Release: 6-Nov-2013
Journal of Nuclear Medicine
Nuclear medicine therapy increases survival for patients with colorectal cancer liver metastases
For patients who fail to respond to current first-line and second-line treatments for colorectal cancer liver metastases (also known as salvage patients), radioembolization with Y-90 microspheres could extend survival according to new research published in the November issue of The Journal of Nuclear Medicine. A systematic review conducted by researchers showed that approximately 50 percent of salvage patients have an overall survival of more than 12 months after this nuclear medicine therapy.

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 5-Nov-2013
International Journal of Medical Engineering and Informatics
Machines learn to detect breast cancer
Software that can recognize patterns in data is commonly used by scientists and economics. Now, researchers in the US have applied similar algorithms to help them more accurately diagnose breast cancer. The researchers outline details in the International Journal of Medical Engineering and Informatics.

Contact: Albert Ang
press@inderscience.com
Inderscience Publishers

Public Release: 5-Nov-2013
mBio
Microbes in the gut help determine risk of tumors
Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study published in mBio®, the online open-access journal of the American Society for Microbiology. The work has implications for human health because it indicates the risk of colorectal cancer may well have a microbial component.

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

Public Release: 5-Nov-2013
Molecular Pharmacology
Drug combination therapy causes cancer cells to 'eat themselves'
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
NIH/National Cancer Institute

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 4-Nov-2013
Cancer Prevention Research
1 dose of HPV vaccine may be enough to prevent cervical cancer
Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute, Ministry of Health of Costa Rica

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 4-Nov-2013
Proceedings of the National Academy of Sciences
Imaging studies may predict tumor response to anti-angiogenic drugs
Advanced imaging techniques may distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly 'normalized' abnormal blood vessels around their tumors and increased blood flow within tumors survived significantly longer than did patients in whom cediranib did not increase blood flow.
National Institutes of Health, National Foundation for Cancer Research

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 4-Nov-2013
EMBO Journal
Why tumor cells go on dangerous tours
Tumors become highly malignant when they acquire the ability to colonize other tissues and form metastases. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a factor that promotes metastasis of colon tumors -- and presents a possible target for therapy.
German Research Foundation

Contact: Luise Dirscherl
dirscherl@lmu.de
49-892-180-2706
Ludwig-Maximilians-Universität München

Public Release: 4-Nov-2013
Molecular Cell
Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway. This is an unexpected finding, as some cancers keep this pathway turned on to fuel their unchecked growth and expansion. Reconciling these opposing roles may give scientists a new perspective on how cancer cells can distort normal cellular functions to maintain their own harmful ways.
National Institutes of Health, Department of Defense, NIH/National Cancer Institute, David H. Koch Graduate Fellowship Fund, National Science Foundation, Howard Hughes Medical Institute, Jane Coffin Childs Memorial Fund

Contact: Nicole Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research

Public Release: 4-Nov-2013
Nature Genetics
Mutations linked to breast cancer treatment resistance
Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients often become resistant to this therapy.
NIH/Clinical Sequencing Exploratory Research Consortium

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 3-Nov-2013
Nature Genetics
Singapore scientists expose molecular secrets of bile duct cancers from different countries
A Singapore-led scientific team discovers critical genes in bile duct cancers from different parts of the world. New molecular insights point to potentially different treatment regimens for the same cancer type depending on underlying genetic alterations.

Contact: Rachel Tan
Rachel.Tan.C.H@nccs.com.sg
659-754-0842
SingHealth

Public Release: 3-Nov-2013
Nature Biotechnology
Is DNA from mom or dad?
A new technique successfully takes on a longstanding challenge in DNA sequencing -- determining whether a particular genetic sequence comes from an individual's mother or father. The method, described in a Ludwig Cancer Research study in Nature Biotechnology, promises to accelerate studies of how genes contribute to disease, improve the process of matching donors with organs and help scientists better understand human migration patterns.
The Ludwig Institute for Cancer Research, Roadmap Epigenome Project

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research

Public Release: 3-Nov-2013
APHA Annual Meeting & Exposition
IU study: Leadership void, not lack of money, slows efforts to address cervical cancer
A study by Indiana University public health researchers found that the opportunity for significant progress in addressing cervical cancer across the country is being squandered -- not because of a lack of money, but because of a void of leadership and organization at the state levels. The study will be discussed on Nov. 3 at the American Public Health Association annual meeting.

Contact: Beth Meyerson
bmeyerson@indiana.edu
812-855-0585
Indiana University

Public Release: 3-Nov-2013
Nature
Life, but not as we know it
A rudimentary form of life that is found in some of the harshest environments on earth is able to sidestep normal replication processes and reproduce by the back door, researchers at The University of Nottingham have found.
Biotechnology and Biological Sciences Research Council

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham

Public Release: 1-Nov-2013
Journal of Clinical Investigation
Liver tropism is key for B cell deletion immunotherapy
In this issue of the Journal of Clinical Investigation, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B cells in live mice after treatment with anti-CD20 antibodies.
Institut Pasteur, INSERM, Fondation pour la Recherche Médicale, European Research Council

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 1-Nov-2013
Clinical Cancer Research
Double-pronged attack could treat common children's cancer
A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumor growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study.

Contact: Lauren King
lauren.king@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 1-Nov-2013
Osteoporosis International
New IOF review provides guidance on fracture prevention in cancer-associated bone disease
A new paper published by an International Osteoporosis Foundation Committee of Scientific Advisors Working Group reviews the epidemiology and pathophysiology of cancer-associated bone disease and provides information about fracture prevention in cancer patients. The review summarizes the pertinent recommendations of leading societies, providing guidance for clinical decision making and information on evidence-based pathways to prevent skeletal-related events and bone loss.

Contact: L. Misteli
info@iofbonehealth.org
41-229-940-100
International Osteoporosis Foundation

Showing releases 1126-1150 out of 1244.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

  Search News Releases

     

 

 

EurekAlert!